Effects of Aging on Methotrexate Elimination
Methotrexate is a commonly prescribed medication used to treat various conditions, including rheumatoid arthritis, psoriasis, and certain types of cancer [1]. As patients age, their ability to eliminate methotrexate from their system changes, affecting the medication's efficacy and toxicity.
Reduced Methotrexate Clearance with Age
Research has shown that methotrexate clearance decreases with age, resulting in increased plasma concentrations and prolonged half-lives [2]. This decline in clearance is attributed to age-related changes in kidney function, reduced liver metabolism, and altered pharmacokinetics [3].
Kidney Function Decline with Age
One of the primary factors contributing to reduced methotrexate clearance is the decline in kidney function that occurs with aging [4]. The kidneys play a crucial role in methotrexate elimination, and impaired kidney function can lead to decreased methotrexate clearance and increased toxicity [5].
Age-Related Changes in Liver Metabolism
Aging also affects liver metabolism, which can impact methotrexate clearance. Older adults have reduced liver blood flow, decreased liver enzyme activity, and altered liver function, all of which can contribute to decreased methotrexate clearance [6].
Pharmacokinetic Implications
The changes in methotrexate clearance with age have significant pharmacokinetic implications. Reduced clearance can lead to increased plasma concentrations, prolonged half-lives, and increased accumulation of the medication in the body [7]. This can result in enhanced toxicity, including increased risk of bone marrow suppression, hepatotoxicity, and other adverse effects [8].
Clinical Implications
Understanding the effects of aging on methotrexate elimination is essential for optimizing treatment in older adults. Healthcare providers should consider the patient's age, kidney function, liver metabolism, and other factors when initiating methotrexate therapy or adjusting doses [9]. Regular monitoring of plasma methotrexate concentrations, kidney function, and liver enzymes can help mitigate the risks associated with methotrexate therapy in older adults [10].
References
[1] DrugPatentWatch.com. (2023). Methotrexate. Retrieved from https://www.drugpatentwatch.com/medicine/methotrexate/
[2] Takeda, H., et al. (2013). Effects of age on methotrexate pharmacokinetics in patients with rheumatoid arthritis. Journal of Clinical Pharmacology, 53(10), 1036-1042.
[3] Matsugo, S., et al. (2016). Age-related changes in methotrexate pharmacokinetics in healthy subjects. European Journal of Clinical Pharmacology, 72(10), 1311-1318.
[4] Lekskanokkul, N., et al. (2017). The effects of aging on kidney function and the implications for methotrexate therapy. Journal of Pharmacy and Pharmacology, 69(8), 1035-1043.
[5] Matsugo, S., et al. (2018). The impact of impaired kidney function on methotrexate pharmacokinetics in patients with rheumatoid arthritis. Rheumatology International, 38(5), 761-768.
[6] Kojima, T., et al. (2019). Age-related changes in liver metabolism and the implications for methotrexate therapy. Journal of Clinical Biochemistry and Nutrition, 65(2), 141-148.
[7] DrugPatentWatch.com. (2023). Methotrexate. Retrieved from https://www.drugpatentwatch.com/medicine/methotrexate/
[8] Matsugo, S., et al. (2020). The effects of aging on methotrexate toxicity in patients with rheumatoid arthritis. Journal of Rheumatology, 47(10), 1425-1432.
[9] Kojima, T., et al. (2020). Optimal methotrexate dosing in older adults: A review of the literature. Journal of Gerontology & Geriatrics, 12(2), 131-138.
[10] DrugPatentWatch.com. (2023). Methotrexate. Retrieved from https://www.drugpatentwatch.com/medicine/methotrexate/